BioAmplified
All protocol guides
AdvancedLongevity12 min read

Longevity Protocols: Telomeres, the GH Axis and Mitochondrial Support

The three mechanisms the longevity peptide field is actually built on, what each does and does not have behind it, and why one of them carries a specific theoretical risk.

Three mechanisms, three evidence levels

The longevity side of this library is not one field. It is at least three distinct biological propositions, and they are at very different stages of evidence. Treating them as a single category is the main error in longevity protocols.

Mechanism one: telomere maintenance

Telomeres are protective caps at the ends of chromosomes that shorten with each cell division. Critically short telomeres trigger cellular senescence — the state in which a cell stops dividing but does not die, and instead releases inflammatory signals. Telomere length correlates with age, which is the observation that launched the field.

Epithalon's proposed mechanism is induction of telomerase, the enzyme that rebuilds telomeres. Telomerase activation has been demonstrated in cultured human cells. Clinical claims about longevity benefit rest on small studies with limited participants and on analogy from animal work.

Why this one carries a specific theoretical risk. Telomerase activation is a hallmark of the large majority of human cancers — cancer cells use it to achieve replicative immortality. Deliberately inducing it outside controlled research is not a neutral act. It might be harmless; it might not. No one knows, and the honest position is that this is the least comfortable mechanism in the library.

Evidence status: cell culture and small studies. Speculative at the level of human outcome.

Mechanism two: the GH and IGF-1 axis

The rationale here is simple: growth hormone and IGF-1 decline with age, and this decline correlates with changes in body composition, bone density and recovery capacity. It is tempting to read that correlation as a deficiency to correct.

The counter-argument is important and often omitted. Suppressing the GH and IGF-1 axis is associated with extended lifespan in several model organisms, and low IGF-1 has been associated with longevity in some human cohorts. The relationship between this axis and ageing is genuinely bidirectional and unresolved. Raising IGF-1 is not straightforwardly anti-ageing.

Evidence status: the hormone response to secretagogues is well documented in controlled settings. The longevity outcome is not established, and the direction of effect is contested.

Mechanism three: mitochondrial and NAD+ support

NAD+ is a coenzyme used by sirtuins and PARPs, enzymes central to DNA repair and mitochondrial function. NAD+ levels decline substantially with age. Raising them is the most biologically well-justified of the three mechanisms.

Animal research is consistent: restoring NAD+ improves metabolic and mitochondrial markers and extends healthspan in mice. Human trials of oral precursors reliably raise blood NAD+ levels. Human outcome data, however, is genuinely mixed — several trials show modest improvements in muscle function or insulin sensitivity, and several show nothing.

Evidence status: strong mechanistic rationale, reliable biomarker effect, unclear clinical outcome.

How to think about combining them

The temptation is to stack all three. The problem is that stacking three poorly-evidenced interventions does not average into a well-evidenced one — it compounds three unknowns, and it makes any observation uninterpretable.

A more useful structure:

  • Pick one mechanism and run it long enough to observe something.
  • Define the marker in advance. For NAD+ precursors, that might be a measurable functional endpoint. For the GH axis, fasting glucose and body composition. For telomeres, there is no useful short-term marker at all — which is itself an argument against starting there.
  • Do not run two interventions you cannot separately attribute an effect to.

The uncomfortable summary

Longevity is the category where the gap between mechanism and outcome is widest, and where confident protocols are least supported. The interventions with the strongest human evidence for healthspan are still the ones nobody sells: sleep, resistance training, protein sufficiency, cardiovascular fitness, and not smoking.

That is not a dismissal of the research. It is a statement about where the evidence currently sits — and about what a protocol built on top of the fundamentals looks like versus one built in place of them.

Dosing context

What is reported, and by whom

Study & clinical-use amounts

**Epithalon:** no human dose-finding studies. The 5–10 mg figures come from the original Russian research protocols, not from controlled trials. **NAD+:** precursor trials use roughly 250–1,000 mg daily of NR or 250 mg of NMN orally; clinics infuse 250–1,000 mg intravenously over one or more hours. **Secretagogues:** human studies measure the growth-hormone pulse after 100–300 mcg of ipamorelin; no trial has tested whether that pulse changes any health outcome.

A dose that appears in a trial or a research protocol is not a dose that has been shown to work for the outcome being claimed. For the mechanisms in this guide — telomerase, NAD+ restoration, IGF-1 — the human outcome data is missing, not just thin.

Community-reported · unverified

**Epithalon:** 5–10 mg daily for ten to twenty days, repeated once or twice a year — a rhythm inherited from the original research protocols, not from human trials. **NAD+/precursors:** 250–1,000 mg by slow infusion in clinics, or 250–500 mg daily of NR/NMN orally. **Ipamorelin:** 200–300 mcg before sleep, often with 100–200 mcg of CJC-1295 (no DAC). All community-reported, unverified and not recommendations.

These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.

Where the reported amounts come from

Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.

Preclinical & non-clinical data

Epithalon: cell and animal work on telomerase activity and pineal regulation, largely from one research tradition, not widely replicated. NAD+: extensively characterised coenzyme biology — redox metabolism, sirtuin, PARP and CD38 signalling — with age-related decline shown in animals and humans, and precursor studies showing restored tissue levels. Secretagogues: animal and small human studies demonstrating growth-hormone release. Only the second has a deep, independently reproduced literature.

Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.

Reported experiences

What people in these communities describe

Public anecdotal reports

The longevity stack has the most optimistic reporting on the site and the least objective reporting anywhere. Users describe better sleep, more vivid dreams and a general sense of steadiness across ten- to twenty-day Epithalon courses repeated once or twice a year — with the honest ones adding that a placebo would look identical. NAD+ infusion accounts describe a burst of clarity for days afterwards at the cost of an unpleasant infusion. Secretagogue users describe deeper sleep within weeks.

What almost nobody in these threads does: measure telomerase, measure NAD+, or track IGF-1. The compounds are each sold on a mechanism, and the reports describe feelings instead. That gap is the most important thing to understand about the entire category.

Where these reports come from

These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.

Referenced in this guide

Compounds mentioned

Open a dossier for the mechanism, dosing reference, side effects and the primary sources.

Ipamorelin

NNC 26-0161

Beginner

Longevity

A selective growth-hormone secretagogue with a clean profile.

GH AxisSleepRecovery
Open dossier

Epithalon

Epitalon, AEDG tetrapeptide

Advanced

Longevity

A telomerase-activating tetrapeptide built on a much bigger claim.

LongevityTelomeresSleep
Open dossier

NAD+

Nicotinamide adenine dinucleotide

Intermediate

Longevity

Not a peptide — but the molecule most of the longevity field orbits.

LongevityMitochondriaEnergy
Open dossier
Keep reading

More advanced protocols

AdvancedMetabolic Health

Metabolic Peptides: GLP-1 and GIP Agonists, In Plain English

The one category here with large randomised trials behind it — what the incretin agonists actually do, what the outcome data shows, and why research powder is a different proposition.

13 min read

AdvancedProtocols

Mitochondria & Energy: SS-31, MOTS-c and NAD+

Mitochondrial support is the fastest-growing corner of the longevity field. Here is what SS-31, MOTS-c and NAD+ actually have behind them — including the one that is not a peptide at all.

13 min read